Skip to main content
BIAF logo

BIAF · bioAffinity Technologies, Inc.

Track BIAF — free
$1.78 -0.07 (-3.78%)
Market Cap
$3.37M
Shares
1.82M
Volume · Nov 20 16.5K Avg daily vol (63 sessions) 3.6M

Price & Indicators

 

Key stats

Close
$1.85
Thu 19 Nov
Open
$2.01
Thu 19 Nov
Average volume, 30 days
148K
shares a session
Short interest
53K
2.9% of shares · 1.0 days to cover
Day range
$1.84$2.11
Open $2.01 Close $1.85
52-week closing range
$1.85$71.10
Close $1.85 97.4% under the high
Short volume, last session
28%
Last earnings
May 15, 2023
Latest filing
10-Q · Nov 6
Price history
Sep 2022 to Nov 2026

Latest documents

2026
Nov 19
Current report 8-K
CyPath Lung Records Highest Monthly Testing Volume in October 2026

bioAffinity Technologies reported record CyPath Lung testing volume in October 2026, the highest monthly volume for its noninvasive lung cancer test. Q3 CyPath Lung test unit sales rose 109% year to date over 2025, and ordering physicians increased 89%.

Other events
4 source passages
bioAffinity Technologies reported record testing volume in October. A record number of CyPath Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test CyPath Lung test unit sales in Q3 doubled year to date over 2025, with solid gains in physician utilization and recurring orders. Together, the 109% increase in test unit sales, 89% increase in ordering physicians and 48% growth in orders from existing physicians indicate broader physician adoption and increased repeat utilization. Open the document at this passage
Nov 17
Current report 8-K Events of Nov 11
Record 235 CyPath Lung tests performed in October, up 29%

bioAffinity Technologies reports a record 235 CyPath Lung tests performed in October 2026, up 29% from October 2025, its highest monthly testing volume. October volume was equivalent to approximately 45% of tests performed in Q3 2026.

Other events
3 source passages
today announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test. In October 2026, 235 CyPath Lung tests were performed, representing a 29% increase compared with October 2025. October 2026 testing volume was equivalent to approximately 45% of the total number of tests performed in Q3 2026. Open the document at this passage
Nov 6
Current report 8-K
CyPath Lung sales rise as revenue falls and loss widens

bioAffinity Technologies reported that CyPath Lung test unit sales increased 100% through Q3 2026, while third-quarter revenue fell to approximately $1.1 million and net loss widened to approximately $5.3 million from approximately $5.1 million.

Financial results
4 source passages
bioAffinity Technologies, Inc. CyPath Lung test unit sales increased 100% through Q3 compared to the first nine months of 2025. Total revenue for the quarter ended September 30, 2026, was approximately $1.1 million, compared with approximately $1.4 million for the same period in 2025. Net loss for the quarter ended September 30, 2026, was approximately $5.3 million, compared with approximately $5.1 million for the third quarter of 2025. Open the document at this passage
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going-concern doubt remains; cash expected to last through March 2027

bioAffinity Technologies reported a net loss of $12.3 million for the nine months ended September 30, 2026, and management concluded there is substantial doubt about its ability to continue as a going concern. Cash and cash equivalents were $2.6 million at September 30, 2026, and $4.6 million as of November 3, 2026, which the company expects will support operations through March 2027.

Revenue $1.07M ▼ 26.0% Net loss $5.28M Diluted EPS -$5.89
Read from the MD&A section
4 source passages
For the nine months ended September 30, 2026 and 2025, we had net losses of $12.3 million and $11.8 million, respectively management concludes that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve (12) months As of September 30, 2026, we had cash and cash equivalents of $2.6 million. As of November 3, 2026, we had cash and cash equivalents of $4.6 million, which we expect will support our operations through March 2027. Open the document at this passage
Oct 29
Current report 8-K
Joins Battle of the Blues Lung Cancer Event November 5

bioAffinity Technologies will join physicians, patients and healthcare providers at the Lung Cancer Initiative of North Carolina's Battle of the Blues on November 5, 2026. It will share CyPath Lung, a noninvasive lung cancer test, at the event.

Other events
2 source passages
The Company will join others committed to advancing lung cancer awareness, research, and patient advocacy on November 5, 2026, at the event where the results of major trials intended to change physician practice will be presented and providers will learn of actionable thoracic oncology results that can enable them to improve treatment and care of lung cancer patients. will join physicians, patients and other healthcare providers at the Lung Cancer Initiative of North Carolina’s Battle of the Blues Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$5.53M
Trailing 12 months
Net income (TTM)
−$15.41M
Trailing 12 months
Revenue growth YoY
-26.0%
Year over year
Operating margin
-246.1%
Trailing 12 months
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 3,327.6%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$2.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,160.8%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
2.9%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −90%
below
Price vs 50-day avg −60%
below
RSI (14) 31
neutral
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −42%
trailing
6-month return −93%
trailing
YTD return −90%
this year
Relative strength −87%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $5 › 200d $18 — 200d above 50d
Institutional flow Distributing
-30% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.94% of shares out · ▼ -19.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Squeeze score 36
low risk · 0–100
Fundamentals
Strong
Revenue growth +14%
Y/Y
Gross margin 0%
EPS growth +62%
Y/Y
Free cash flow $-9.4M
Balance sheet $5.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 209%
annualized · 1-yr
Max drawdown −97%
past year
ATR 24.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 15, 2023
Net revenues · next 12 months (fourth quarter 2023 to third quarter 2024) $8.4M – $9M
Guided vs delivered · last 1 settled
Net revenues 2023
guided $2.1M – $2.3M
$7.9M Beat +259.1%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−90% Bearish
Price vs 50-day avg
−60% Bearish
RSI (14)
31 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $5 › 200d $18 — 200d above 50d
Institutional flow Distributing
-30% holders QoQ · +1 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.94% of shares out · ▼ -19.8% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
16 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $71
vs 200-day avg -90% vs 50-day avg -60%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
awarded U.S. and foreign patents 22 now —
clinical sites 11 As of September 30, 2026 —
CyPath Lung testing revenue $1.1M first nine months of 2026 —
number of ordering physicians 89% third quarter of 2026 —
pending applications 36 now —
Physicians already ordering CyPath Lung tests 48% third quarter of 2026 —
CyPath Lung test reports delivered 1,097 Six months ended June 30, 2026 —
CyPath® Lung diagnostic test volume 216% Q2 2026 —
CyPath® Lung test results delivered 622 the three months ended June 30, 2026 filing —
Existing client CyPath Lung orders 71% Six months ended June 30, 2026 —
Physician offices and clinics ordering CyPath Lung 122% Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BIAF
bioAffinity Technologies, Inc.
this stock
$3.37M — +14.5% — 2.9%
TMO
Thermo Fisher Scientific Inc.
$255.19B +18.9% +14.5% 36.3 1.3%
DHR
Danaher Corp
$160.10B -0.6% +8.5% 37.2 1.2%
IDXX
Idexx Laboratories Inc
$54.33B +1.9% +10.4% 46.5 3.0%
A
Agilent Technologies, Inc.
$49.43B +28.9% +6.4% 34.5 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
16
% held
16.1%
Net QoQ
+109.4K sh
Top holder
HRT FINANCIAL LP
Held Float
View
Held by Funds
Fund positions
5
View
Short & Settlement
Short Interest Falling
Shares short
53.5K
Days to cover
1.0d
Change
-13.2K sh
View
Short Volume
Short vol %
28%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
5.0K
Value
$14.7K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
63.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$6.2M
Net income (FY)
$-14.9M
EPS diluted
$-129.90
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 19, 2026
This year
64

bioAffinity Technologies reported record CyPath Lung testing volume in October 2026, the highest monthly volume for its noninvasive lung cancer test. Q3 CyPath Lung test unit sales rose 109% year to date over 2025, and ordering physicians increased 89%.

View
Exempt Offerings
Offering
$4.0M
Filed
Oct 29, 2024
View
Earnings & Events
Webcasts
Last webcast
May 15, 2023
View
Investor Relations
Latest news
bioAffinity Technologies Reports…
Published
Nov 17, 2026
View

Performance

5D 20D 120D MTD YTD
BIAF -20.9% -41.6% -93.0% -36.4% -89.6%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -15.5% -35.4% -87.3% -31.2% -94.5%
Key facts CIK 1712762 CUSIP 09076W406 13F (30d) 21 filings 14 filers Visit website Investor relations